Studies on the procurement of blood coagulation factor VIII
Item Status
Embargo End Date
Date
Authors
Abstract
Coagulation factor VIII is needed for the
treatment of patients with haemophilia. Requirements
for factor VIII are important in determining the numbers
of blood donations to be collected in Scotland. The
final yield of factor VIII:C in products prepared from
blood plasma, when prepared either in the Transfusion
Centres or the National Fractionation Centre, is relatively
low (30-40%). Improvements in these processes would have
major implications for the Transfusion Service.
Present technology requires the freezing of
plasma from blood donations prior to the preparation of
cryoprecipitate; this may then be processed further to
produce factor VIII concentrate. In this study, the
effects of using different anticoagulants (citrate,
heparin), of varying the rate of freezing and the
duration of storage on the factor VIII content of plasma
and subsequent products have been investigated. The
influence of ABO blood group and of drug induced enhancement
on levels of factor VIII in starting plasma were
also studied. Improvements in the mode of preparing cryoprecipitate
from plasma have been made on the basis of
the observed effects on processing plasma of different
quality (collection procedure, age, etc .) and by various
methods. Investigation of the mechanism of cryoprecipitation
has led to the development of a high-yield method for the preparation of factor VIII from unfrozen plasma
by precipitation with hydrophilic polymers.
In the course of this work, methods were
developed for the isolation of factor VIII and fibronectin
and immunological assays for these and other proteins
(fibrinogen), based on immunoprecipitation and immunoradiometric
methods, were set up. The immunoradiometric
methods were used to follow the recovery and survival of
factor VIII components following infusion into patients
deficient in this protein.
Based on the work described in this thesis,
recommendations will be made on the possibilities for
improved procurement of factor VIII from blood donations.
This item appears in the following Collection(s)

